Increased intestinal permeability to oral chromium (51Cr) -EDTA in human Type 2 diabetes

Diabetic Medicine

Volumn 31, Issue 5, 2014, Pages 559-563

  Horton, F ^a   Wright, J ^b   Smith, L ^b   Hinton, P J ^a   Robertson, M D ^b  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EDETATE CHROMIUM CR 51; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CHROMIUM; EDETIC ACID;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG PENETRATION; DRUG URINE LEVEL; GAMMA COUNTER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTESTINE MUCOSA PERMEABILITY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; URINE VOLUME; BLOOD; CASE CONTROL STUDY; CELL MEMBRANE PERMEABILITY; CYTOLOGY; INTESTINE; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; URINE;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CELL MEMBRANE PERMEABILITY; CHROMIUM RADIOISOTOPES; DIABETES MELLITUS, TYPE 2; EDETIC ACID; HUMANS; INTERLEUKIN-6; INTESTINAL ABSORPTION; INTESTINES; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898904073     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12360     Document Type: Article

References (20)

1. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279-288.
2. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87: 1219-1223.
3. Clemente-Postigo M, Queipo-Ortuno MI, Murri M, Boto-Ordonez M, Perez-Martinez P, Andres-Lacueva C et al. Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. J Lipid Res 2012; 53: 973-978.
4. Brenner C, Simmonds RE, Wood S, Rose V, Feldmann M, Turner J. TLR signalling and adapter utilization in primary human in vitro differentiated adipocytes. Scand J Immunol 2012; 76: 359-370.
5. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249.
6. Creely SJ, McTernan PG, Kusminski CM. Fisher fM, Da Silva NF, Khanolkar M et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740-747.
7. Harte AL, Varma MC, Tripathi G, McGee KC, Al-Daghri NM, Al-Attas OS et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care 2012; 35: 375-382.
8. Secondulfo M, de Magistris L, Sapone A, Di Monda G, Esposito P, Carratu R. Intestinal permeability and diabetes mellitus type 2. Minerva Gastroenterol Dietol 1999; 45: 187-192.
9. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002; 34: 385-396.
10. 51Cr-EDTA test for intestinal permeability. Lancet 1984; 2: 523.
11. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002; 97: 2000-2004.
12. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-1294.
13. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
14. Choi K, Lee SS, Oh SJ, Lim SY, Lim SY, Jeon WK et al. The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr 2007; 26: 57-62.
15. Anderson AD, Jain PK, Fleming S, Poon P, Mitchell CJ, MacFie J. Evaluation of a triple sugar test of colonic permeability in humans. Acta Physiol Scand 2004; 182: 171-177.
16. de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obes Rev 2011; 12: 449-458.
17. 51Cr-EDTA. Am J Gastroenterol 1985; 80: 770-773.
18. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
19. Suzuki T, Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab 2010; 7: 19.
20. Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 2012; 92: 1020-1032.